


OVERVIEW

One of the great strengths of proteomics is its potential to aid in the generation of novel hypotheses and/or to lead to new insights into biological systems. The aim of this study was to isolate and identify novel proteins that are involved in the process of tumor initiation and progression through comparison of a tumorigenic vs. a mutant non-tumorigenic embryonal carcinoma (EC) cell line. This application described how the use of iTRAQ isobaric tagging combined with off-line multidimensional liquid chromatography have enabled the identification and differential profiling of low level proteins from a cancer cell line.

INTRODUCTION

Embryonal carcinoma (EC) cells are stem cells of tetracarinosam-tumors that develop in the gonads of both humans and mice. These tumor cells are essentially indistinguishable, at least in terms of differentiative and neoplastic potentials, from the embryonal stem (ES) cells of early (peri-implantation) mammalian embryo. We have used retroviral insertion to create a mutant embryonal carcinoma cell line NR1-6, which is unique in its morphological, adhesive, tumorigenic, and differential properties (Figure 1). Genetic analysis of mutant, hybrid, and revertant cell lines indicates there is only a single retroviral insertion site that we have mapped to the proximal portion of the mouse X chromosome. Mouse mammary gland and brain expressed sequence tags (ESTs) have greater than 97% homology to a region within the > 18 kb of the insertion site flanking genomic DNA that we have sequenced. Utilizing these ESTs, we have identified two transcripts expressed in parental, but not in mutant cells. These are 3.8 and 2.3 kb. The predominant transcript, ~2.3 kb, contains two exons, the second of which is disrupted by insertion. Expression analysis indicates that these transcripts are widely expressed both temporally and spatially. However, although expression of these transcripts is highly reproducible and has been confirmed by multiple assays, neither we, nor various different sequencing facilities, have been able to find an open reading frame (ORF) within them. Thus it is likely that they represent regulatory RNAs. We have conducted large-scale differential display (over 80 primer pairs and 90,000 bands) and micro-array analyses (1076 genes of ESTs) to identify downstream targets of these transcripts or RNAs with little success. That is to say, that by this technology only these two transcripts, and one for a bHLH gene called MyoR, are differentially expressed. We have tested the MyoR gene in transient transfections and have found that its expression, or lack thereof, does not regulate the mutant phenotypes. Thus, we have been unable to identify the relevant altered downstream transcripts. It is possible that the amplification steps of the PCR based differential display and microarray techniques are damping out differences. To identify proteins that may play a role for those phenotype changes, we employed proteomic approach for comparative study the protein profiles from those two cell lines.

Figure 1. Morphology of NR1-0 and NR1-6




EXPERIMENTAL

Protein preparation and iTRAQ isobaric labeling. EC Cells (6×10^6) were cultured in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum. The cells were washed with cold PBS 3 times and scrapped in 400 μ l sample buffer (100 mM Tris-HCl, 8M Urea, 0.05% SDS, 5 mM TBP, pH 8.3). The sample mixtures were probe-sonicated on ice for 5x20 seconds followed by iodoacetamide alkylation for 1hr. Protein concentration was measured by MicroBCA by using a Pierce protein assay kit before the reaction was quenched by the addition of DTT. Equal aliquots (500 μ g) from each lysate were then tryptic digested overnight at 37°C. The tryptic peptide mixture from each sample was desalted with a C18 cartridge followed by the iTRAQ labeling as described in the iTRAQ protocol (Figure 2).

Off-line strong cation exchange chromatography. The labeled samples were then pooled and acidified to a total volume of 2.0 ml followed by injection into a Agilent 1100 HPLC system with a Zorbax 300-SCX column (4.6 ID x250 mm). Solvent A was 5mM K2HPO4 + 25% acetonitrile, pH 3.0 and B was 350 mM KCl +A. Peptides were eluted from the column with a 40 min mobile phase B gradient. A total of 26 fractions were collected. The samples were dried by a speed-vac prior to LC-MS/MS analysis.

On-line nano-LC ESI QqTOF MS Analysis. The nanobore LC system was from Dionex and interfaced to a QSTAR XL QqTOF mass spectrometer with a NanoSpray ion source. The Picofrit column (Magic C18, 100 A pore 75 μ m ID x150 mm) was packed in house. Solvent A was 3% CH3CN+ 0.1% formic acid+0.01%TFA, and B was 98% CH3CN+0.1% formic acid +0.01% TFA. Peptides mixture (reconstituted in 200 μ l of 5% formic acid) was injected and eluted from the column with a 110 min mobile phase B gradient (5 -5 %B in 5 min, 5 -18%B in 10 min, 18-30% B in 65min, 30 -60%B in 10 min, 60-90 % B in 10 min, and 90-90% in 5 min) at a flow rate of 250 nl/min. The mass spectrometer was operated in an information dependent acquisition mode whereby following the interrogation of MS data (m/z 350-1600) using a 1 second survey scan, ions were selected for MS/MS analysis based on their intensity (>20 cpm) and charge state (+2, +3, and +4). Total of 3 product ion scans (2,3,3 s each) were set from each survey scan. Rolling collision energies were chosen automatically based on the m/z and charge-state of the selected precursor ions. The IDA Extensions II script was set to one repetition before dynamic exclusion. Identification and quantitation was performed using PRO QUANT software (AB, Forst City, CA) using IPI mouse database (v3.14), with an MS and MS/MS mass tolerance of 0.15 Da. Protein identification with confidence scores of >90% were considered.

Figure 2. Workflow for the identification of changes in the proteome in EC line, using iTRAQ isobaric tagging



RESULTS

Figure 3. Fractionation of pooled iTRAQ tagged peptides through SCX. Fraction 0.8 ml are collected




Figure 4. Representative MS/MS spectrum of labeled GVVDSEDLPLNISR obtained from LC-MS/MS duplex analysis of protein mixture. The expansion region shows the "reporter" ion distribution obtained upon peptide fragmentation




Table 1. Summary of significant protein expression change in NR1-0 vs. NR1-6 comparative study

Accession	Protein Name	Ratio 114:115	P Val 114:115
IP0030043	Heat shock protein HSP 90-alpha	1.6695	0.0001
IP0048061	PREDICTED: similar to heat shock protein 8	1.2069	0.0031
IP00407103	NOD-derived CD11c v-vv dendritic cells cDNA, RIKEN full-length enriched library, clone:F	1.3099	0.0028
IP00121761	Peroxisome oxidin 1	1.2952	0
IP00460722	Alpha-enolase	1.3816	0.0024
IP00108021	78 kDa glucose-regulated protein precursor	1.1996	0.012
IP00130224	60S ribosomal protein L6	1.2705	0.0111
IP00130031	Stress-70 protein, mitochondrial precursor	1.4861	0.0052
IP00130105	CRL-1722 L5178Y-R cDNA, RIKEN full-length enriched library, clone:J73002805 product:G	1.3341	0.001
IP00460932	Elongation factor 2	1.5011	0.0001
IP00225614	D-3-phosphoglycerate dehydrogenase	1.391	0.0014
IP00460812	ATP synthase beta chain, mitochondrial precursor	1.2548	0.0028
IP00450434	T-complex protein 1, alpha subunit B	1.252	0.006
IP00108413	Elongation factor 1-gamma	1.1691	0
IP00224153	Activated spleen cDNA, RIKEN full-length enriched library, clone:F83022505 product:asp	1.5162	0.0015
IP00460981	Pyridyl-prolyl cis-trans isomerase A	1.3723	0.0041
IP00460291	Splice isoform 2 of 14-3-3 protein theta	1.5128	0.0197
IP00128023	C-1-neraldehyde synthase, cytoplasmic	1.3933	0.0186

Accession	Protein Name	Ratio 114:115	P Val 114:115
IP00126105	Laminin receptor 1	1.2737	0.0455
IP00244506	60S ribosomal protein L13	1.3274	0.0165
IP00130752	60S acidic ribosomal protein P2	1.2442	0.0181
IP00117463	Guanine nucleotide-binding protein beta subunit 2-like 1	1.2723	0.0184
IP00460884	Threonyl-tRNA synthetase, cytoplasmic	1.3757	0.0094
IP00230053	12 days embryo eyeball cDNA, RIKEN full-length enriched library, clone:D230033A18	1.5162	0.0003
IP00130594	Nuclear autoantigenic sperm protein	1.4362	0.0033
IP00111412	60S ribosomal protein L4	1.4166	0.0466
IP00228064	Adult male epididymis cDNA, RIKEN full-length enriched library, clone:923001109 product	1.3397	0.0363
IP00201561	18 kDa protein	1.2448	0.0174
IP00457041	PREDICTED: similar to ribosomal protein L27a	1.4185	0.0159
IP00115620	Phosphoserine aminotransferase	1.3355	0.0354
IP00247251	2 days neonate thymus thymic cells cDNA, RIKEN full-length enriched library, clone:E430	1.1359	0.0153
IP00130561	40S ribosomal protein S21	1.2797	0.0047
IP00257051	12 days embryo spiral ganglion cDNA, RIKEN full-length enriched library, clone:D130054D	1.2059	0.0001
IP00263301	40S ribosomal protein S16	1.1553	0.0104
IP00118853	Eukaryotic translation elongation factor 1 delta, isoform a	1.2085	0.0258
IP00454601	40S ribosomal protein S12	1.4259	0.0214
IP00460161	PREDICTED: similar to 60S ribosomal protein L18	1.4196	0.0288
IP00459571	2 days neonate thymus thymic cells cDNA, RIKEN full-length enriched library, clone:C920	1.2028	0.0004
IP00114201	Glutamate dehydrogenase 1, mitochondrial precursor	1.3495	0.0332
IP00228183	40S ribosomal protein S20	1.3355	0.0002
IP00122913	17 days embryo kidney cDNA, RIKEN full-length enriched library, clone:J920160L24 product	1.4336	0.0044
IP00223711	Splice isoform 2 of RNA-binding region containing protein 2	1.3238	0.0067
IP00247142	Hypothetical protein MGC103372	1.1643	0.0463
IP00240204	51 kDa protein	1.7597	0.0216
IP00233553	Fabp3n	1.5758	0.0371
IP00114381	Hsc70-interacting protein	1.2856	0.0276
IP00126321	Splice isoform A of Heat-shock protein beta-1	2.2099	0.0102
IP00122463	26S proteasome non-ATPase regulatory subunit 2	1.0988	0.0333
IP00233553	Uridine phosphorylase 1	0.6718	0.0036
IP00174421	PREDICTED: similar to HNP2-like protein 1 (High mobility group-like nuclear protein 2 h	1.1848	0.0149
IP00260602	PREDICTED: similar to eukaryotic translation initiation factor 5A	1.2819	0.0048
IP00214201	13 kDa protein	1.3055	0.0135
IP00453812	Leucyl-tRNA synthetase, cytoplasmic	1.6116	0.005
IP00119241	Small nuclear ribonucleoprotein Sm D3	1.3924	0.0441
IP00116273	T-complex protein 1, epsilon subunit	1.3084	0.0006
IP00115671	Splice isoform 2 of Neuronal alpha-glucosidase AB precursor	1.4276	0.0396
IP00204172	PREDICTED: similar to acidic nuclear phosphoprotein 32 family, member B isoform 2	1.4041	0.0463
IP00128201	Metastasis-associated protein MTA2	2.832	0.0251
IP00423042	Activated spleen cDNA, RIKEN full-length enriched library, clone:F830029A18 product:K0	1.1979	0.0024
IP00231757	Adult male thymus cDNA, RIKEN full-length enriched library, clone:5830469E03	0.8143	0.0242
IP00124441	Splice isoform 1 of 6-phosphofruktokinase type C	1.4156	0.0298
IP00122221	DNA topoisomerase 2-alpha	1.1268	0.0432
IP00153862	CRL-1722 L5178Y-R cDNA, RIKEN full-length enriched library, clone:J730071A103	1.1872	0.0101
IP00474802	product:Si	1.4799	0.0221
IP00458683	Separin	1.6185	0.0138
IP00126421	Serine/threonine-protein kinase 38	0.332	0.0471
IP00255861	PREDICTED: similar to melanoma antigen, family B, 1	1.6837	0.0239
IP00127403	Transketolase	1.2068	0.0499
IP00130981	7-dehydrocholesterol reductase	1.6028	0.0255
IP00113912	T-cell ecto-ADP-ribosyltransferase 1 precursor	1.6646	0.018

CONCLUSIONS

- iTRAQ isobaric labeling coupled with off-line multidimensional chromatography has been developed and applied for analysis protein changes in a cancer cell line
- Total of 26 SCX fractions were used for the LC-MS/MS analysis resulted in 10498 MS/MS spectra. Total of 3638 spectra were identified with a confidence of 99%
- Over 337 proteins including integral membrane proteins, hydrophobic proteins and proteins with extreme pIs have been identified in an EC mutant cell line.
- Total of 67 up-regulated proteins and 3 down-regulated proteins with statistic significant differences were identified in NR1-0 cell line
- Future work will use other independent approaches such as western, immuno-histochemical and activity assays to confirm and verify the observed changes

ACKNOWLEDGEMENTS

The UAlbany Proteomics Facility is supported by the SUNY Research Foundation. The QSTAR XL mass spectrometer used in this work was funded through the National Institutes of Health under Grant IS10 RR01782-01A1